10-Q: Pluri Inc. Q3 2026 Financials Show Revenue Decline, Increased R&D

Pluri Inc. reported a decrease in revenues for the nine and three months ended March 31, 2026, alongside an increase in R&D and G&A expenses, while highlighting ongoing liquidity concerns.

Summary

• Pluri Inc. reported revenues of $681,000 for the nine months ended March 31, 2026, down from $938,000 in the same period last year. For the three-month period, revenues were $167,000, a decrease from $427,000 in the prior year.
• Cost of revenues also decreased to $424,000 for the nine months and $111,000 for the three months, reflecting lower project activity.
• Research and Development (R&D) expenses, net, increased significantly to $11.7 million for the nine months (up from $8.9 million) and $4.0 million for the three months (up from $3.0 million).
• General and Administrative (G&A) expenses rose to $7.9 million for the nine months (up from $7.1 million) and $2.6 million for the three months (up from $2.5 million).
• The company reported a net loss of $19.2 million for the nine months ended March 31, 2026, compared to a net loss of $15.5 million in the prior year. The three-month net loss was $6.2 million, compared to $6.3 million in the prior year.
• As of March 31, 2026, Pluri Inc. had a working capital deficit of $21.5 million and total deficit of $13.0 million.
• The company's cash and cash equivalents, restricted cash, and short-term bank deposits totaled $9.5 million as of March 31, 2026.
• Management estimates that the company has sufficient resources to meet its operating obligations for less than three months from the issuance date of the financial statements, raising substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to declining revenues, increased operating expenses, a significant net loss, and a critical liquidity situation that raises substantial doubt about the company's ability to continue as a going concern.

Positives

• The company's net loss per share improved to $(1.90) for the nine months ended March 31, 2026, from $(2.56) in the prior year, and $(0.55) for the three months, from $(0.94) in the prior year, primarily due to an increase in the weighted average number of shares outstanding.
• Cash provided by investing activities increased to $8.3 million for the nine months ended March 31, 2026, from $5.0 million in the prior year, mainly from proceeds from short-term deposits.
• The company regained compliance with Nasdaq Listing Rule 5550(b)(2) regarding market value of listed securities.
• Progress continues in advancing activities across foodtech, AgTech, and cell-based aesthetics and wellness subsidiaries, with collaborations in place.
• The company received approval for the second year of funding from the IIA for its collaboration with Bar-Ilan University.

Negatives

• Revenues decreased by approximately 27.4% for the nine-month period and 60.4% for the three-month period compared to the prior year.
• Net loss increased by $3.7 million for the nine-month period ended March 31, 2026, compared to the prior year.
• The company has a significant working capital deficit of $21.5 million as of March 31, 2026.
• Management estimates the company has less than three months of operating liquidity, raising substantial doubt about its ability to continue as a going concern.
• The European Investment Bank (EIB) has reserved its rights under the Finance Contract, although discussions for restructuring are ongoing.
• The National Institute of Allergy and Infectious Diseases (NIAID) terminated its contract with Pluri Biotech for convenience.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to insufficient liquidity and recurring operating losses.
• The company requires significant additional capital to support commercialization and R&D activities, with no assurance of obtaining it.
• The EIB loan of $27.4 million is due on June 1, 2026, and discussions for restructuring are ongoing with an uncertain outcome.
• Geopolitical tensions in the Middle East, including ongoing hostilities involving Israel, Iran, and terrorist organizations, may affect economic and market conditions and impact the business.
• Developments in international trade policy, such as tariffs and trade barriers, could negatively impact operations.
• The company's ability to maintain compliance with Nasdaq Listing Rule 5550(b)(2) is a constant consideration.

Future Outlook

The company anticipates not generating significant revenues from product sales in the next twelve months and expects near-term revenues to be less than operating costs. Pluri Inc. may need to secure additional liquidity to fund commercialization and R&D. Management estimates less than three months of operating liquidity, raising substantial doubt about its ability to continue as a going concern. Success is dependent on obtaining additional capital, entering partnerships, providing CDMO services, restructuring the EIB loan, and securing other funding sources.

Management Comments

• Management estimates that the Company has sufficient resources to meet its operating obligations for a period of less than three months from the issuance date of these interim unaudited condensed consolidated financial statements.
• These conditions raise substantial doubt about the Companys ability to continue as a going concern.
• The Company is addressing its liquidity issues by implementing initiatives to allow the continuation of its activities.
• The Company's ability to successfully carry out its business plan is primarily dependent upon its ability to (1) obtain sufficient additional capital, (2) enter licensing or other commercial partnerships and collaboration agreements, (3) provide CDMO services to clients, (4) enter into an agreement with the EIB regarding a loan restructuring, and (5) receive other sources of funding, including non-dilutive sources such as grants.
• There is no assurance, however, that the Company will be successful in obtaining an adequate level of financing needed for the long-term development and commercialization of its products, or any financing at all.

Industry Context

StockSavvy.ai notes that Pluri Inc.'s focus on cell therapy, regenerative medicine, and CDMO services places it within a rapidly evolving and competitive biotechnology sector. The company's diversification into AgTech and Food Tech, while potentially offering new revenue streams, also spreads its resources thin. The significant increase in R&D expenses, coupled with declining revenues and a critical liquidity situation, highlights the high-risk, high-reward nature of companies in this space, where substantial investment is required for product development and regulatory approval.

Comparison to Industry Standards

• Companies in the biotechnology sector often experience periods of high R&D investment and fluctuating revenues, especially those in early-stage development or commercialization.
• The 'going concern' warning is a critical indicator, and while not uncommon in early-stage biotech, it requires close monitoring of cash runway and financing activities.
• Competitors in the CDMO space, such as Lonza or Catalent, typically operate with more established revenue streams and larger operational scales, making Pluri's CDMO segment a smaller, albeit growing, part of its overall strategy.
• In regenerative medicine, companies like Mesoblast or Athersys have also faced significant financial and clinical development challenges, underscoring the capital-intensive nature of the field.

Related Party Transactions

• On December 8, 2025, the Company entered into a Securities Purchase Agreement with Chutzpah Holdings LP, a limited partnership beneficially owned by Mr. Alexandre Weinstein, a non-U.S. investor and an existing shareholder and director of the Company, for a private placement offering.

Stakeholder Impact

• Shareholders: The declining financial performance, increased net loss, and going concern warning could negatively impact shareholder value and confidence. Capital raises may be dilutive.
• Creditors: The EIB loan is due soon, and ongoing discussions for restructuring introduce uncertainty for the lender.
• Employees: The company's financial instability and cost-reduction plans may lead to job insecurity or reduced benefits.
• Suppliers and Service Providers: Potential delays in payments or reduced business volume due to the company's liquidity constraints.

Next Steps

• Continue discussions with the EIB regarding potential restructuring of the EIB Loan, including a possible extension of its maturity date.
• Pursue obtaining sufficient additional capital through various financing activities.
• Enter into licensing or other commercial partnerships and collaboration agreements.
• Provide CDMO services to clients.
• Continue to advance activities across foodtech, AgTech, and cell-based aesthetics and wellness subsidiaries.
• Evaluate new accounting pronouncements for potential impact on financial statement disclosures.

Key Dates

Recommendation

The filing indicates a deteriorating financial position with declining revenues, increasing losses, and a critical liquidity crunch that casts significant doubt on the company's ability to continue as a going concern. While there are ongoing efforts to secure funding and restructure debt, the immediate financial risks and the uncertainty surrounding future financing make it a high-risk investment. The improved loss per share is largely an artifact of share dilution rather than operational improvement.

Keywords

Pluri Inc., 10-Q, Quarterly Report, Biotechnology, Cell Therapy, Regenerative Medicine, CDMO, AgTech, Food Tech, Financial Results, R&D Expenses, Liquidity, Going Concern